# SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19

> **NCT06050460** · PHASE1 · UNKNOWN · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SA55 Injection
- **OTHER:** Placebo for SA55 injection

## Key facts

- **NCT ID:** NCT06050460
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-15
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050460, "SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06050460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*